TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01738906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltodextrin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltodextrin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltodextrin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vodka

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vodka

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vodka

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: butter cake MSF
Description: chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: butter cake MSF
Description: chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: butter cake consumption
Description: chewing for 6 min on 40 gram cake and then swallow it.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: butter cake consumption
Description: chewing for 6 min on 40 gram cake and then swallow it.
Study: NCT01766024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
Study: NCT03204175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT Plus
Description: * Group handwashing facilities~* Daily group handwashing and toothbrushing activities~* Sanitation operation and maintenance manuals for school officials~* Toilet cleaning consumable~* Toilet and handwashing station maintenance kits~* Soap, toothbrushes, and toothpaste
Study: NCT02292706

Intervention type: DRUG
Intervention: Ribavirin

Intervention type: DRUG
Intervention: LDV/SOF
Description: Exposure of interest for participants who received LDV/SOF in a previous Gilead study for chronic HCV infection.

Intervention type: DRUG
Intervention: LDV/SOF
Description: Exposure of interest for participants who received LDV/SOF in a previous Gilead study for chronic HCV infection.

Intervention type: DRUG
Intervention: SOF/VEL
Description: Exposure of interest for participants who received SOF/VEL in a previous Gilead study for chronic HCV infection.
Study: NCT00934739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide, Dexamethasone
Description: Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
Study: NCT02292706

Intervention type: DRUG
Intervention: SOF/VEL
Description: Exposure of interest for participants who received SOF/VEL in a previous Gilead study for chronic HCV infection.

Intervention type: DRUG
Intervention: SOF/VEL/VOX
Description: Exposure of interest for participants who received SOF/VEL/VOX in a previous Gilead study for chronic HCV infection.
Study: NCT01663246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Sample
Description: Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Sample
Description: Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
Study: NCT05015959

Intervention type: OTHER
Intervention: observation
Description: quality
Study: NCT00513331

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
Study: NCT02292706

Intervention type: DRUG
Intervention: Other SOF-Based Regimen
Description: The other SOF-based regimens may have included the following:~* BMS-790052 (Daclatasvir) + GS-7977 (SOF) with or without RBV~* LDV/SOF + GS-9669, GS-7977 (SOF) + with or without RBV + TMC-435 (Simeprevir)~* LDV/SOF + Vedroprevir (VDV), LDV/SOF + GS-9669 (250 mg and 500 mg)~* LDV/SOF + VDV + RBV~* Simeprevir + SOF~* TMC-435 (Simeprevir) + VEL/SOF

Intervention type: OTHER
Intervention: Ineligible parent treatment
Description: Participants were enrolled from ineligible parent treatment group.
Study: NCT01100775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
Study: NCT00513331

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
Study: NCT01100775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
Study: NCT04331002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilretta
Description: ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mL normal saline
Study: NCT00918515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: intravenous solution given once as intravenous infusion over 30 minutes
Study: NCT01705106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00513331

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation protocol
Description: Ablation using the HALO 360 system according to protocol established by BARRX, Inc.

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation protocol
Description: Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
Study: NCT01705106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study: NCT04383054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'More minutes' conversation (Moving medicine)
Description: For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 'one minute' conversation (Moving medicine)
Description: For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
Study: NCT02128412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)
Description: Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)
Description: Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
Study: NCT04189458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program
Description: Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (30 min), cool-down (5 min), and finishing ritual (5 min). At the initial stage, the activation of different muscle groups will be performed. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities and will privilege IPS. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation - physical fitness (strength, balance and agility) - alternating with exercises mainly focused on cognitive stimulation - CF (planning ability, solving-problems, IPS, attention and DT performance). At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants sign an attendance sheet regarding the session, including perceived exertion (Borg Scale) and satisfaction (Caregiver Treatment Satisfaction questionnaire).
Study: NCT04534764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A with cosmetic pattern
Description: TEST
Study: NCT04420403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Stabilazation Exercise (CSE)
Description: The CSE program aims to maintain a neutral spine position and activate deep cervical muscles during exercises. It is performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program will start with postural training and then the cervical bracing technique with the activation of deep neck flexors for CSE was performed. The patients will be asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises will be increased weekly. It will be carried out 2 days a week for 6 weeks (12 sessions) by the supervisor physiotherapist.
Study: NCT04599595

Intervention type: DEVICE
Intervention: Peristeen (Coloplast)
Description: Patients with severe intestinal dysfunction impairment (PAC QoL score ≥ 32) will be offered the adoption of the TAI (Transanal Irrigation) with Peristeen Device as a way to manage their own evacuation, replacing any other measure used until that moment (suppositoires, clisms exceptionally cc) with the exception of the possible intake of macrogols and/or prebiotics and/or probiotics which instead patients can continue. This treatment will be proposed to all patients with severe impairment of intestinal function.~The TAI training with Peristeen will be carried out at the surgical clinic of the Surgical Department of the Ferrara University Hospital, Italy, by the health personnel involved in the study, usually in a single session, but more sessions may be necessary, with the continuation of the TAI for 4 weeks or with patient's exclusion from the study if the guarantees of appropriate use of the device will not be reached.
Study: NCT00605345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms sc 4-weekly (starting dose)
Study: NCT00513331

Intervention type: PROCEDURE
Intervention: Endoscopic mucosal resection protocol
Description: Excision of lesion using DUETTE, marketed by Wilson-Cook
Study: NCT03370666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNT
Description: High flow nasal therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIV
Description: Noninvasive ventilation
Study: NCT04552808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yimitasvir Phosphate
Description: Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yimitasvir Phosphate
Description: Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yimitasvir Phosphate
Description: Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yimitasvir Phosphate
Description: Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
Study: NCT01300572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant
Study: NCT01300572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indium In 111 Anti-CD45 Monoclonal Antibody BC8
Description: Given IV (dosimetric dose)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Description: Given via central line (therapeutic dose)
Study: NCT04723680

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative semi structured interview

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative semi structured interview

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative semi structured interview

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative semi structured interview

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative semi structured interview
Study: NCT03779581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Correction exercises
Description: Active self-correction exercises to restore movements in different planes as close to physiologically normal as possible.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthotic devices
Description: the orthotic devices designed to correct the scoliosis curve
Study: NCT01791478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BYL719
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological studies
Description: Correlative studies
Study: NCT02883101

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises
Study: NCT02400021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prometrium
Study: NCT02239315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor RNA Disruption Assay™ (RDA)
Description: Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
Study: NCT01600937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theoretical & practical exercise counseling
Description: 2 sessions/ per wk for 1 month
Study: NCT01674205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine placebo (Leibovitz-15 [L-15])

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine placebo (FluMist®)
Study: NCT01347996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: histamine dihydrochloride and IL-2
Description: Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg \[16,400 IU/kg\] body weight twice daily for 10, 21 day cycles
Study: NCT02006849

Intervention type: DRUG
Group type: OTHER
Intervention: Acthar
Description: FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.

Intervention type: DRUG
Group type: OTHER
Intervention: Acthar
Description: FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.